The objective of this study was to compare different pharmacokinetic parameters of a local ("X") and reference (Tavanic) formulations of levofloxacin 250 mg tablets after oral administration of a single dose under fasting condition. Thirteen blood samples were collected from each of the eight Bangladeshi healthy male volunteers over 24 hours after oral administration of the drugs. Serum levofloxacin concentrations were determined by HPLC assay using UV detection, and pharmacokinetic parameters were determined by the non-compartmental method. Mean ± SD of C max , AUC 0-24 , AUC 0-α , T max , t 1/2 , k el , were 4.33 ± 1.16 and 4.56 ± 1.51 µg/mL, 45.90 ± 8.74 and 37.77 ± 9.94 hr-µg /mL, 79.94 ± 32.80 and 66.85 ± 35.43 hr-µg/mL, 1.22 ± 0.49 and 1.28 ± 0.41, 19.90 ± 11.49 and 21.00 ± 16.39 hr, 0.04 ± 0.02 and 0.05 ± 0.03 hr -1 for the local ("X") and reference formulation, respectively. From the paired t-test, the p-values for two formulations were found to be 0.182, 0.412 and 0.725 for AUC 0-24 , AUC 0-α , and C max respectively. The 90% confidence intervals of the mean of the difference between log-transformed values for C max were almost within the bioequivalence accepted range of 80% to 125%, namely: (78.90%, 118.36%); but for AUC 0-24 and AUC 0-α the values were are beyond the acceptable range. (100.83%, 146.52%) and (94.34%, 157.89%) respectively. The results indicate that the two formulations are not bioequivalent for both the rate and extent of absorption.
INTRODUCTION
Levofloxacin((-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate) is a quinoline carboxylic acid derivative with a broad antibacterial activity against both grampositive and gram-negative bacteria. 1 It has been shown to be effective against a variety of pathogens such as members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and commonly isolated A single dose pharmacokinetic study of levofloxacin showed that an oral dose of levofloxacin was rapidly and almost completely absorbed. Levofloxacin showed excellent tissue penetration by absorbing two-thirds of those in plasma. The extent of penetration is similar to other fluroquinolones. 5, 6 Peak plasma concentrations are usually attained one to two hours after oral dosing. 7, 8 Co-administration of levofloxacin with Calciumfortified orange juice decreases the values of C max and t max of levofloxacin by 14% to 18% and 50% respectively. 9, 10 The aim of this study was to compare the rate and extent of absorption of two formulations of levofloxacin 250 mg tablet; a local (test) formulation: ("X"), manufactured by a well reputed leading Bangladeshi pharmaceutical company and a reference formulation: Tavanic, manufactured by SanofiAventis, UK under the licensing authority of Ortho McNeil, USA; under fasting condition.
MATERIALS AND METHODS

Subjects.
Eight healthy, non-smoking, adult Bangladeshi male volunteers were randomly selected in the study. Their mean age ± SD was 25.63 ± 1.41 (24 to 28) years. Their mean body weight and mean height were 69.50 ± 4.72 (60 to 75) kg and 1.74 ± 0.04 (1.68 to 1.80) m respectively, giving a mean body mass index (BMI) of 22.89 ± 1.50 (20.50 to 25.0) kg/m 2 . Subjects were selected after examining the medical history, physical check up, chest X-ray, ECG, serological screening for infectious disease, and urine analysis. Participation in the study was limited to those with no evidence of significant abnormal hematology and serum chemistry. Exclusion criteria included any history of a significant gastrointestinal condition that could potentially impair the absorption or disposition of the study medicine, previous history of allergy to any fluoruquinolone, need for any chronic medication (e.g. theophylline, antacid, glibenclamide, phenytoin, iron or vitamins), donation of blood within 30 days preceding the first dose of the study or use of a investigational agent within 30 days of study entry. Potential subjects were also excluded if they use any medication within one day before administration of the first dose. The volunteers were asked to abstain from taking any medication (including over-thecounter drugs) throughout the study; and from smoking, taking alcohol or caffeine or consuming xanthene-containing beverages or food for at least 48 hours prior to, and throughout the study. Any incidence of vomiting or any other adverse events resulted in the exclusion of the subject from the study. They were informed about the risks, benefits, procedures, and aims of the study, as well as their rights as research subjects. Study design. In the study, 8 volunteers were selected randomly. All volunteers received single 250 mg film coated tablet of both formulations: Reference formulation (A) or Test formulation (B). Volunteers were randomly divided into two groups (Group-1 and 2) consisting of 4 volunteers in each group. Group-1 received treatment A followed by treatment B with a seven-day washout period. This sequence of treatment is denoted by AB. Group-2 received treatment B followed by treatment A after the same washout period. This sequence of treatment is denoted as BA. In the first period, Group-1 received treatment A and Group-2 received treatment B. In the second period Group-1 received treatment B and Group-2 received treatment A. This type of study design is known as crossover design in statistical literature. 11 Each volunteer received the treatment with 250 mL of water in the morning after overnight fasting. A standard lunch was allowed after 4 hours of dosing. The volunteers were ambulatory during the study but were prohibited from strenuous activity. Volunteers were monitored constantly for the period of 24 hours by a medical doctor.
Blood sampling. The timing of blood collection was planned according to the previously reported value of time to reach peak serum concentration (T max ) and serum elimination half-life (t 1/2 ). [12] [13] [14] [15] [16] An intravenous cannula was placed into the volunteers' forearm vein before drug administration and left in place until the 24-hour blood sample was collected. Venous blood samples were collected before, and at 0.25, 0.50, 0.75, 1.00, 1.50, 2, 3, 5, 7, 9, 12 and 24 hours after administration of drug. The blood samples were collected in coded, evacuated tubes, kept 30 minutes for clotting and centrifuged at room temperature (3000 rpm for 15 minutes). The serum was collected in coded eppendorf tubes and serum protein was separated by precipitation with ethanol followed by centrifugation at 10,000 rpm for 5 minutes. The serum was collected and stored at −80°C until analyzed.
Levofloxacin level determination by HPLC. Levofloxacin was separated at room temperature on a 5-µm (particle-size), 4.6 X 250-mm Kromasil ODS C 18 and Kromasil C 18 5-µm insert. The compounds of interest were detected by using a UV detector at 293 nm wavelength. The mobile phase consists of 0.05 M (mol/L) citric acid : 1 M ammonium acetate and acetonitrile (77 : 1 : 22 v/v) and was delivered at a flow rate of 1.0 mL/min. Samples were injected in the HPLC system by an autosampler. The retention time was 4.8445 ± 0.0016 minutes. The standard curves were linear over the concentration ranges of 25 to 1000 ng/mL with a mean correlation coefficient of 0.9958. The lower limit of quantification (LLOQ) of levofloxacin in the serum was found to be 25 ng/mL. All the blood samples were analyzed within one week of collection. The precision and accuracy were investigated with quality control (QC) samples at concentrations of 25, 50,100, 250, 500, 1000 ng/mL. The results are shown in the Pharmacokinetic analysis. The following pharmacokinetic parameters were directly calculated by the standard non-compartmental analysis: (a) Maximum serum concentration (C max ), time to reach peak serum concentration (T max ). (b) The elimination half-life (t 1/2 ) was calculated as t 1/2 = (ln 2)/K el , where K el is the apparent elimination rate constant. K el was calculated by using the software WinNonlin. Statistical Analysis: Let y ijk be the observed value of a pharmacokinetic parameter corresponding to the subject k in period j of group i. The following model is assumed for y ijk :
where µ is the general mean, S ik is the random effect of subject k in group i, Π j is the effect of period j, τ d[i, j] is the effect of treatment administered in period j of group i, λ d[i,j−1] is the carry-over (sequence) effect of the treatment administered in period j−1 of group i with λ[i,0]=0 and ε ijk is the random error term. It is assumed that random terms S ik and ε ijk follow normal distribution with same mean 0 and variance σ 2 and σ 2 s , respectively. Carryover effect can be tested by comparing corresponding mean sum of squares with the between subject mean sum of squares (
) and period of a treatment effects are tested by comparing corresponding mean squares with the within subject mean squares ( ).
In our analysis, log-transformed value of the pharmacokinetic parameters AUC 0−24 , AUC 0-α , C max , K el , t 1/2 , and C max / AUC 0-α are used in the model (1) . The model (1) can be fitted by usual statistical software. We have used statistical software R for fitting the model and drawing inferences about the parameters 18 .
Besides fitting the model, we also reported the approximate 90% confidence interval for the difference between two formulations only for the pharmacokinetic parameters AUC 0−24 , AUC 0-α , C max , and C max / AUC 0-α .
RESULTS AND DISCUSSION
The mean (± SD) serum concentration-time profile of the two formulations, shown in the Figure  1 , was closely similar and superimposable. Central and dispersion measures for all pharmacokinetic parameters for both formulations are shown in Table 2 . From this, the mean values of C max were found to be 4.56 (SD = 1.51) µg/mL for reference product and 4.33 (SD = 1.16) µg/mL for local (test) product. For the mean values of T max (hr) were found to be 1.28 (SD = 0.41) µg/mL for reference product and 1.22 (SD = 0.49) µg/mL for local (test) product. The mean values of AUC 0-24 were found to be 37.77 (SD = 9.94) µg.hr/mL for reference and 45.90 (SD = 8.74) µg.hr/mL for local product. AUC is important in determining the bioavailability and bioequivalence of a drug product. For all volunteers the values of AUC 0-24 were found to be greater than 80% of AUC 0-α . The mean AUC 0-α values were found to be 66.85 (SD = 35.43) µg.hr/mL and 79.94 (SD = 32.80) µg.hr/mL for reference and local product respectively. Other pharmacokinetic parameters such as t 1/2, k el, AUMC 0-24, AUMC 0-α and MRT were also determined. Table 3 features that the change of C max, AUC 0-24 and AUC 0-α were found to be insignificant (p>0.1). Table 4 shows the ANOVA of the model (1). It shows after controlling the effects of period, sequence, and subject there is no significant difference between the two formulations for all the pharmacokinetic parameters we considered. Period effects were found to be insignificant for all the parameters. The insignificant sequence effects indicate no carry-over effect of the two formulations. Subject variations were also found to be insignificant at 10 percent level of significance. Table 5 shows the 90% confidence intervals of the ratios (Test/Reference) between the two formulations regarding AUC 0-24, AUC 0-α , C max and C max / AUC 0-α.
Assessment of bioequivalence of local product to reference product is required to exclude any clinically important differences in the rate or extent at which the active entity of the drugs becomes available at the site of action. Two drugs are considered to be bioequivalent if they are pharmaceutically equivalent and their bioavailabilities are so similar that they are unlikely to produce clinically relevant differences in regard to safety and efficacy. The aim of this study was to compare the bioavailability of two formulations of levofloxacin 250 mg tablet, a local (test) formulation, "X", and a reference formulation, Tavanic. The study revealed that at 90% confidence interval (Table 5) AUC 0-24 , AUC 0-α , and C max were found to be (100.83%, 146.52%), (94.34%, 157.89%) and (78.90%, 118.34%) respectively from log-transformed data. The values for C max are found almost within the acceptable range but the values for AUC 0-24 and AUC 0-α are beyond the accepted range of 80% to 125%. [20] [21] Moreover, a further evaluation of the rate of absorption was performed by analyzing the C max / AUC 0-α , since this parameter has been proposed to better reflect the absorption rate. 22 The 90%
confidence intervals for this parameter also indicated bioequivalence.
In conclusion, the two formulations can not be considered bioequivalent in regard to the extent and rate of absorption and therefore not interchangeable.
